BR0311826A - Inibidores da interação gpib-vwf, sua preparação e uso - Google Patents

Inibidores da interação gpib-vwf, sua preparação e uso

Info

Publication number
BR0311826A
BR0311826A BR0311826-6A BR0311826A BR0311826A BR 0311826 A BR0311826 A BR 0311826A BR 0311826 A BR0311826 A BR 0311826A BR 0311826 A BR0311826 A BR 0311826A
Authority
BR
Brazil
Prior art keywords
gpib
compounds
preparation
formula
vwf
Prior art date
Application number
BR0311826-6A
Other languages
English (en)
Inventor
Otmar Klingler
Melitta Just
Kuniya Sakurai
Naoyuki Fukuchi
Original Assignee
Ajinomoto Co Inc Pharmaceutica
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc Pharmaceutica, Aventis Pharma Gmbh filed Critical Ajinomoto Co Inc Pharmaceutica
Publication of BR0311826A publication Critical patent/BR0311826A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

"INIBIDORES DA INTERAçãO GPIb.vWF, SUA PREPARAçãO E USO". A presente invenção refere-se a compostos da fórmula (1): na qual R1, R2, A, B, D, E, n, m ou o têm os significados indicados abaixo. Os compostos da fórmula 1 são compostos farmacologicamente ativos valiosos. Eles são inibidores reversíveis da interação entre o fator de von Willebrand da proteína no plasma (vWF) e o complexo de glicoproteínas Ib-IX-V do receptor de plaquetas sanguíneas (GPlb). Eles exibem efeito antitrombótico e são adequados, por exemplo, para a terapia e profilaxia de doenças aterotrombóticas.
BR0311826-6A 2002-06-06 2003-06-06 Inibidores da interação gpib-vwf, sua preparação e uso BR0311826A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02012590A EP1369420A1 (en) 2002-06-06 2002-06-06 Inhibitors of the GPib - vWF interaction
PCT/EP2003/005955 WO2003104221A1 (en) 2002-06-06 2003-06-06 Inhibitors of the gpib -vwf interaction, their preparation and use

Publications (1)

Publication Number Publication Date
BR0311826A true BR0311826A (pt) 2005-03-29

Family

ID=29433122

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311826-6A BR0311826A (pt) 2002-06-06 2003-06-06 Inibidores da interação gpib-vwf, sua preparação e uso

Country Status (9)

Country Link
EP (2) EP1369420A1 (pt)
JP (1) JP4455326B2 (pt)
AT (1) ATE353082T1 (pt)
AU (1) AU2003274686A1 (pt)
BR (1) BR0311826A (pt)
CA (1) CA2488193A1 (pt)
DE (1) DE60311578T2 (pt)
MX (1) MXPA04011408A (pt)
WO (1) WO2003104221A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR043507A1 (es) * 2003-03-14 2005-08-03 Lundbeck & Co As H Derivados de anilina sustituidos y composiciones farmaceuticas
CA2519061A1 (en) * 2003-03-14 2004-09-23 H. Lundbeck A/S Substituted aniline derivatives
WO2005033079A1 (ja) 2003-09-30 2005-04-14 Eisai Co., Ltd. ヘテロ環化合物を含有する新規な抗真菌剤
EP1782811A4 (en) * 2004-08-09 2010-09-01 Eisai R&D Man Co Ltd INNOVATIVE ANTIPALUDITIC AGENT CONTAINING A HETEROCYCLIC COMPOUND
US7829585B2 (en) 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
US8183264B2 (en) 2006-09-21 2012-05-22 Eisai R&D Managment Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
WO2008136279A1 (ja) 2007-04-27 2008-11-13 Eisai R & D Management Co., Ltd. ヘテロ環置換ピリジン誘導体の塩またはその結晶
CN101808518A (zh) 2007-06-27 2010-08-18 默沙东公司 作为组蛋白脱乙酰酶抑制剂的吡啶基和嘧啶基衍生物
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
CN103327972A (zh) * 2010-10-11 2013-09-25 里兰斯坦福初级大学理事会 取代的苯甲酰胺及其用途
WO2013155338A2 (en) 2012-04-12 2013-10-17 The Board Of Trustees Of The Leland Stanford Junior University Substituted benzamides and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW301607B (pt) * 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
WO1998027815A1 (en) * 1996-12-20 1998-07-02 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
EP1509516A1 (en) 2005-03-02
CA2488193A1 (en) 2003-12-18
EP1369420A1 (en) 2003-12-10
EP1509516B1 (en) 2007-01-31
DE60311578D1 (de) 2007-03-22
WO2003104221A1 (en) 2003-12-18
JP2005528459A (ja) 2005-09-22
ATE353082T1 (de) 2007-02-15
DE60311578T2 (de) 2007-11-15
AU2003274686A1 (en) 2003-12-22
AU2003274686A8 (en) 2003-12-22
JP4455326B2 (ja) 2010-04-21
MXPA04011408A (es) 2005-09-30

Similar Documents

Publication Publication Date Title
BR0311826A (pt) Inibidores da interação gpib-vwf, sua preparação e uso
CY1112274T1 (el) Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν
BR0016396A (pt) Novos antagonistas do receptor p2x7 para uso no tratamento de doenças inflamatórias, imunes ou cardiovasculares
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
BR9808998A (pt) Imidazóis substituìdos úteis no tratamento de doenças inflamatórias
CY1107505T1 (el) Πουρινικες ενωσεις και χρησεις τους ως προσδεματα υποδοχεων κανναβιδοειδων
DE69034103D1 (de) Imidazoalkensäure
EA200500595A1 (ru) Новые алкиновые соединения, обладающие антагонистическим в отношении мсн действием, и содержащие эти соединения лекарственные средства
CY1107871T1 (el) Παραγωγα πυριμιδινης και η χρηση τους ως ρυθμιστων cb2
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
DE69818831D1 (de) Indolderivate als mcp-1 rezeptor antagonisten
NO20026064D0 (no) Nye forbindelser
DE60041973D1 (de) Substituierte piperidin-verbindungen als modulatoren der chemokine receptor aktivität
CY1104993T1 (el) 4-(πιπεριδυλ- και πυρρολιδινυλ-αλκυλ-ουρεϊδο)-κινολινες ως ανταγωνιστες του υποδοχεα ουροτασινης ii
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR0208741A (pt) Derivados de piperidina
ATE202776T1 (de) Piperinderivate als neurokininantagoniste
NO20052794L (no) Antibakterielle indolonoksazolidinoner intermediater for fremstilling av disse og farmasoytiske prepareter inneholdende disse
HUP0500034A2 (hu) N-Aril-N'-(aril-cikloalkil)-karbamid-származékok mint MCH antagonisták és ezeket hatóanyagként tartalmazó gyógyszerkészítmények
CY1105039T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
DE68906609T2 (de) Dopamin-vorlaeufer.
SE0101038D0 (sv) Novel compounds
ATE196768T1 (de) Neue 6-hydroxy und 6-oxo-androstan verbindungen mit kardioaktivität und pharmazeutische präparate davon

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.